Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 418


Disability Related to Chronic Graft-versus-Host Disease.

Hamilton BK, Storer BE, Wood WA, Pidala JA, Cutler CS, Martin PJ, Chen G, Flowers ME, Lee SJ.

Biol Blood Marrow Transplant. 2019 Oct 24. pii: S1083-8791(19)30676-7. doi: 10.1016/j.bbmt.2019.10.019. [Epub ahead of print]


Phase I/II multisite trial of optimally dosed clofarabine and low-dose TBI for hematopoietic cell transplantation in acute myeloid leukemia.

Krakow EF, Gyurkocza B, Storer BE, Chauncey TR, McCune JS, Radich JP, Bouvier ME, Estey EH, Storb R, Maloney DG, Sandmaier BM.

Am J Hematol. 2020 Jan;95(1):48-56. doi: 10.1002/ajh.25665. Epub 2019 Nov 8.


Carfilzomib for Treatment of Refractory Chronic Graft-versus-Host Disease: A Chronic GVHD Consortium Pilot Phase II Trial.

Pidala J, Jaglowski S, Im A, Chen G, Onstad L, Storer B, Kurukulasuriya C, Lee SJ.

Biol Blood Marrow Transplant. 2020 Feb;26(2):278-284. doi: 10.1016/j.bbmt.2019.09.002. Epub 2019 Sep 6.


Rituximab-based allogeneic transplant for chronic lymphocytic leukemia with comparison to historical experience.

Shadman M, Maloney DG, Storer B, Sandmaier BM, Chauncey TR, Smedegaard Andersen N, Niederwieser D, Shizuru J, Bruno B, Pulsipher MA, Maziarz RT, Agura ED, Hari P, Langston AA, Maris MB, McSweeney PA, Storb R, Sorror ML.

Bone Marrow Transplant. 2020 Jan;55(1):172-181. doi: 10.1038/s41409-019-0660-8. Epub 2019 Sep 3.


The Chronic Graft-versus-Host Disease Failure-Free Survival (cGVHD-FFS) Index.

Pidala JA, Hamilton BK, Martin PJ, Onstad L, Storer BE, Palmer J, Alousi A, Cutler C, Jagasia MH, Chen GL, Arora M, Flowers ME, Lee SJ.

Biol Blood Marrow Transplant. 2019 Dec;25(12):2468-2473. doi: 10.1016/j.bbmt.2019.07.040. Epub 2019 Aug 5.


Impact of clinical, cytogenetic, and molecular profiles on long-term survival after transplantation in patients with chronic myelomonocytic leukemia.

Woo J, Choi DR, Storer BE, Yeung C, Halpern AB, Salit RB, Sorror ML, Woolston DW, Monahan T, Scott BL, Deeg HJ.

Haematologica. 2019 Jul 9. pii: haematol.2019.218677. doi: 10.3324/haematol.2019.218677. [Epub ahead of print]


Allogeneic Hematopoietic Cell Transplantation in the Outpatient Setting.

Granot N, Storer BE, Cooper JP, Flowers ME, Sandmaier BM, Storb R.

Biol Blood Marrow Transplant. 2019 Nov;25(11):2152-2159. doi: 10.1016/j.bbmt.2019.06.025. Epub 2019 Jun 28.


Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial.

Sandmaier BM, Kornblit B, Storer BE, Olesen G, Maris MB, Langston AA, Gutman JA, Petersen SL, Chauncey TR, Bethge WA, Pulsipher MA, Woolfrey AE, Mielcarek M, Martin PJ, Appelbaum FR, Flowers MED, Maloney DG, Storb R.

Lancet Haematol. 2019 Aug;6(8):e409-e418. doi: 10.1016/S2352-3026(19)30088-2. Epub 2019 Jun 24.


Revised Acute Myeloid Leukemia Composite Model Using the 2017 European LeukemiaNet Risk Classification.

Sorror ML, Storer BE, Nyland J, Estey EH.

JAMA Oncol. 2019 Jul 1;5(7):1062-1064. doi: 10.1001/jamaoncol.2019.0902. No abstract available.


Organ Changes Associated with Provider-Assessed Responses in Patients with Chronic Graft-versus-Host Disease.

Martin PJ, Storer BE, Palmer J, Jagasia MH, Chen GL, Broady R, Arora M, Pidala JA, Hamilton BK, Lee SJ.

Biol Blood Marrow Transplant. 2019 Sep;25(9):1869-1874. doi: 10.1016/j.bbmt.2019.05.008. Epub 2019 May 11.


Limited Utility of Outpatient Surveillance Blood Cultures in Hematopoietic Cell Transplant Recipients on High-Dose Steroids for Treatment of Acute Graft-versus-Host-Disease.

Stohs E, Chow VA, Liu C, Bourassa L, Miles-Jay A, Knight J, Sweet A, Storer BE, Mielcarek M, Pergam SA.

Biol Blood Marrow Transplant. 2019 Jun;25(6):1247-1252. doi: 10.1016/j.bbmt.2019.01.031. Epub 2019 Feb 1.


Second allogeneic hematopoietic cell transplantation for relapse after first allografts.

Gyurkocza B, Storb R, Chauncey TR, Maloney DG, Storer BE, Sandmaier BM.

Leuk Lymphoma. 2019 Jul;60(7):1758-1766. doi: 10.1080/10428194.2018.1542149. Epub 2019 Jan 22.


Total body irradiation dose escalation decreases risk of progression and graft rejection after hematopoietic cell transplantation for myelodysplastic syndromes or myeloproliferative neoplasms.

Monaco F, Scott BL, Chauncey TR, Petersen FB, Storer BE, Baron F, Flowers ME, Deeg HJ, Maloney DG, Storb R, Sandmaier BM.

Haematologica. 2019 Jun;104(6):1221-1229. doi: 10.3324/haematol.2018.199398. Epub 2019 Jan 10.


Prognostic Performance of the Augmented Hematopoietic Cell Transplantation-Specific Comorbidity/Age Index in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation from Alternative Graft Sources.

Elsawy M, Storer BE, Milano F, Sandmaier BM, Delaney C, Salit RB, Rashad AH, Woolfrey AE, Appelbaum FR, Storb R, Sorror ML.

Biol Blood Marrow Transplant. 2019 May;25(5):1045-1052. doi: 10.1016/j.bbmt.2018.11.030. Epub 2018 Nov 28.


Comprehensive B Cell Phenotyping Profile for Chronic Graft-versus-Host Disease Diagnosis.

Rozmus J, Kariminia A, Abdossamadi S, Storer BE, Martin PJ, Lee SJ, Wolff D, Arora M, Cutler C, Schultz KR.

Biol Blood Marrow Transplant. 2019 Mar;25(3):451-458. doi: 10.1016/j.bbmt.2018.11.007. Epub 2018 Nov 14.


Disability related to chronic graft -versus-host disease after alternative donor hematopoietic cell transplantation.

Fatobene G, Storer BE, Salit RB, Lee SJ, Martin PJ, Cheng GS, Carpenter PA, Balgansuren G, Petersdorf EW, Delaney C, Sandmaier BM, Milano F, Flowers ME.

Haematologica. 2019 Apr;104(4):835-843. doi: 10.3324/haematol.2018.202754. Epub 2018 Nov 15.


Long-term follow up of tandem autologous-allogeneic hematopoietic cell transplantation for multiple myeloma.

Maffini E, Storer BE, Sandmaier BM, Bruno B, Sahebi F, Shizuru JA, Chauncey TR, Hari P, Lange T, Pulsipher MA, McSweeney PA, Holmberg L, Becker PS, Green DJ, Mielcarek M, Maloney DG, Storb R.

Haematologica. 2019 Feb;104(2):380-391. doi: 10.3324/haematol.2018.200253. Epub 2018 Sep 27.


Rates and Risk Factors for Post-Traumatic Stress Disorder Symptomatology among Adult Hematopoietic Cell Transplant Recipients and Their Informal Caregivers.

Liang J, Lee SJ, Storer BE, Shaw BE, Chow EJ, Flowers ME, Krakow EF, Bar M, Syrjala KL, Salit RB, Kurukulasuriya CE, Jim HSL.

Biol Blood Marrow Transplant. 2019 Jan;25(1):145-150. doi: 10.1016/j.bbmt.2018.08.002. Epub 2018 Aug 9.


Incorporating Physical Function and Cognition Into Mortality Risk Assessment for Acute Myeloid Leukemia-Reply.

Sorror ML, Storer BE, Estey EH.

JAMA Oncol. 2018 Jul 1;4(7):1014-1015. doi: 10.1001/jamaoncol.2018.0677. No abstract available.


Inosine Monophosphate Dehydrogenase Pharmacogenetics in Hematopoietic Cell Transplantation Patients.

McCune JS, Storer B, Thomas S, McKiernan J, Gupta R, Sandmaier BM.

Biol Blood Marrow Transplant. 2018 Sep;24(9):1802-1807. doi: 10.1016/j.bbmt.2018.04.006. Epub 2018 Apr 12.


Non-myeloablative allogeneic hematopoietic cell transplantation for relapsed or refractory Waldenström macroglobulinemia: evidence for a graft-versus-lymphoma effect.

Maffini E, Anderson LD Jr, Sandmaier BM, Green DJ, Storer BE, Niederwieser D, Maziarz RT, Maloney DG, Storb R.

Haematologica. 2018 Jun;103(6):e252-e255. doi: 10.3324/haematol.2017.184176. Epub 2018 Mar 15. No abstract available.


Murine chronic graft-versus-host disease proteome profiling discovers CCL15 as a novel biomarker in patients.

Du J, Flynn R, Paz K, Ren HG, Ogata Y, Zhang Q, Gafken PR, Storer BE, Roy NH, Burkhardt JK, Mathews W, Tolar J, Lee SJ, Blazar BR, Paczesny S.

Blood. 2018 Apr 12;131(15):1743-1754. doi: 10.1182/blood-2017-08-800623. Epub 2018 Jan 18.


Tandem autologous/allogeneic hematopoietic cell transplantation with bortezomib maintenance therapy for high-risk myeloma.

Green DJ, Maloney DG, Storer BE, Sandmaier BM, Holmberg LA, Becker PS, Fang M, Martin PJ, Georges GE, Bouvier ME, Storb R, Mielcarek M.

Blood Adv. 2017 Nov 9;1(24):2247-2256. doi: 10.1182/bloodadvances.2017010686. eCollection 2017 Nov 14.


Transplant Conditioning with Treosulfan/Fludarabine with or without Total Body Irradiation: A Randomized Phase II Trial in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia.

Deeg HJ, Stevens EA, Salit RB, Ermoian RP, Fang M, Gyurkocza B, Sorror ML, Fatobene G, Baumgart J, Burroughs LM, Delaney C, Doney K, Egan DN, Flowers MED, Milano F, Radich JP, Scott BL, Sickle EJ, Wood BL, Yeung C, Storer BE.

Biol Blood Marrow Transplant. 2018 May;24(5):956-963. doi: 10.1016/j.bbmt.2017.12.785. Epub 2017 Dec 20.


Impact of copy neutral loss of heterozygosity and total genome aberrations on survival in myelodysplastic syndrome.

Yeung CCS, McElhone S, Chen XY, Ng D, Storer BE, Deeg HJ, Fang M.

Mod Pathol. 2018 Apr;31(4):569-580. doi: 10.1038/modpathol.2017.157. Epub 2017 Dec 15.


Success of Immunosuppressive Treatments in Patients with Chronic Graft-versus-Host Disease.

Lee SJ, Nguyen TD, Onstad L, Bar M, Krakow EF, Salit RB, Carpenter PA, Rodrigues M, Hall AM, Storer BE, Martin PJ, Flowers ME.

Biol Blood Marrow Transplant. 2018 Mar;24(3):555-562. doi: 10.1016/j.bbmt.2017.10.042. Epub 2017 Nov 10.


Anti-Platelet-Derived Growth Factor Receptor Alpha Chain Antibodies Predict for Response to Nilotinib in Steroid-Refractory or -Dependent Chronic Graft-Versus-Host Disease.

Chen GL, Carpenter PA, Broady R, Gregory TK, Johnston LJ, Storer BE, Beumer JH, Qiu J, Cerda K, Le R, Otani JM, Liu H, Ross MA, Arai S, Flowers MED, McCarthy PL, Miklos DB.

Biol Blood Marrow Transplant. 2018 Feb;24(2):373-380. doi: 10.1016/j.bbmt.2017.10.021. Epub 2017 Oct 16.


Reversal of Low Donor Chimerism after Hematopoietic Cell Transplantation Using Pentostatin and Donor Lymphocyte Infusion: A Prospective Phase II Multicenter Trial.

Bar M, Flowers MED, Storer BE, Chauncey TR, Pulsipher MA, Thakar MS, Bethge W, Storb R, Maloney DG, Sandmaier BM.

Biol Blood Marrow Transplant. 2018 Feb;24(2):308-313. doi: 10.1016/j.bbmt.2017.10.016. Epub 2017 Oct 12.


Hematopoietic Cell Transplantation for Myelofibrosis: the Dynamic International Prognostic Scoring System Plus Risk Predicts Post-Transplant Outcomes.

Samuelson Bannow BT, Salit RB, Storer BE, Stevens EA, Wu D, Yeung C, Fang M, Petersdorf EW, Linenberger ML, Woo J, Sorror ML, Doney K, Sandmaier BM, Deeg HJ, Scott BL.

Biol Blood Marrow Transplant. 2018 Feb;24(2):386-392. doi: 10.1016/j.bbmt.2017.09.016. Epub 2017 Sep 29.


Development and Validation of a Novel Acute Myeloid Leukemia-Composite Model to Estimate Risks of Mortality.

Sorror ML, Storer BE, Fathi AT, Gerds AT, Medeiros BC, Shami P, Brunner AM, Sekeres MA, Mukherjee S, Peña E, Elsawy M, Wardyn S, Whitten J, Moore R, Becker PS, McCune JS, Appelbaum FR, Estey EH.

JAMA Oncol. 2017 Dec 1;3(12):1675-1682. doi: 10.1001/jamaoncol.2017.2714.


The Use of Ex Vivo Generated Regulatory T-Cell Preparations in a Canine Lung Allograft Model.

Abrams KV, Hwang B, Nash RA, Georges GE, Lamm W, Storer B, Madtes DK, Glenny R, Mulligan MS.

Transplantation. 2017 Oct;101(10):e326-e327. doi: 10.1097/TP.0000000000001868. No abstract available.


An endpoint associated with clinical benefit after initial treatment of chronic graft-versus-host disease.

Martin PJ, Storer BE, Inamoto Y, Flowers MED, Carpenter PA, Pidala J, Palmer J, Arora M, Jagasia M, Arai S, Cutler CS, Lee SJ.

Blood. 2017 Jul 20;130(3):360-367. doi: 10.1182/blood-2017-03-775767. Epub 2017 May 11.


Predictive Value of Clinical Findings and Plasma Biomarkers after Fourteen Days of Prednisone Treatment for Acute Graft-versus-host Disease.

McDonald GB, Tabellini L, Storer BE, Martin PJ, Lawler RL, Rosinski SL, Schoch HG, Hansen JA.

Biol Blood Marrow Transplant. 2017 Aug;23(8):1257-1263. doi: 10.1016/j.bbmt.2017.04.029. Epub 2017 May 3.


Association of Plasma CD163 Concentration with De Novo-Onset Chronic Graft-versus-Host Disease.

Inamoto Y, Martin PJ, Paczesny S, Tabellini L, Momin AA, Mumaw CL, Flowers MED, Lee SJ, Carpenter PA, Storer BE, Hanash S, Hansen JA.

Biol Blood Marrow Transplant. 2017 Aug;23(8):1250-1256. doi: 10.1016/j.bbmt.2017.04.019. Epub 2017 Apr 25.



Bhatia S, Storer BE, Nghiem P.

J Natl Cancer Inst. 2017 Oct 1;109(10). doi: 10.1093/jnci/djx053. No abstract available.


Validation of single nucleotide polymorphisms in invasive aspergillosis following hematopoietic cell transplantation.

Fisher CE, Hohl TM, Fan W, Storer BE, Levine DM, Zhao LP, Martin PJ, Warren EH, Boeckh M, Hansen JA.

Blood. 2017 May 11;129(19):2693-2701. doi: 10.1182/blood-2016-10-743294. Epub 2017 Mar 7.


Mutational analysis in serial marrow samples during azacitidine treatment in patients with post-transplant relapse of acute myeloid leukemia or myelodysplastic syndromes.

Woo J, Howard NP, Storer BE, Fang M, Yeung CC, Scott BL, Deeg HJ.

Haematologica. 2017 Jun;102(6):e216-e218. doi: 10.3324/haematol.2016.162909. Epub 2017 Feb 16. No abstract available.


CD25 Blockade Delays Regulatory T Cell Reconstitution and Does Not Prevent Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation.

Locke FL, Pidala J, Storer B, Martin PJ, Pulsipher MA, Chauncey TR, Jacobsen N, Kröger N, Walker I, Light S, Shaw BE, Beato F, Laport GG, Nademanee A, Keating A, Socie G, Anasetti C.

Biol Blood Marrow Transplant. 2017 Mar;23(3):405-411. doi: 10.1016/j.bbmt.2016.12.624. Epub 2016 Dec 19.


Recipient and donor age impact the risk of developing chronic GvHD in children after allogeneic hematopoietic transplant.

Watkins BK, Horan J, Storer B, Martin PJ, Carpenter PA, Flowers ME.

Bone Marrow Transplant. 2017 Apr;52(4):625-626. doi: 10.1038/bmt.2016.328. Epub 2016 Dec 19. No abstract available.


Genome-wide minor histocompatibility matching as related to the risk of graft-versus-host disease.

Martin PJ, Levine DM, Storer BE, Warren EH, Zheng X, Nelson SC, Smith AG, Mortensen BK, Hansen JA.

Blood. 2017 Feb 9;129(6):791-798. doi: 10.1182/blood-2016-09-737700. Epub 2016 Nov 21.


Factors Determining Responses to Azacitidine in Patients with Myelodysplastic Syndromes and Acute Myeloid Leukemia with Early Post-Transplantation Relapse: A Prospective Trial.

Woo J, Deeg HJ, Storer B, Yeung C, Fang M, Mielcarek M, Scott BL.

Biol Blood Marrow Transplant. 2017 Jan;23(1):176-179. doi: 10.1016/j.bbmt.2016.10.016. Epub 2016 Oct 24.


Replication of associations between genetic polymorphisms and chronic graft-versus-host disease.

Martin PJ, Fan W, Storer BE, Levine DM, Zhao LP, Warren EH, Flowers ME, Lee SJ, Carpenter PA, Boeckh M, Hingorani S, Yan L, Hu Q, Preus L, Liu S, Spellman S, Zhu X, Pasquini M, McCarthy P, Stram D, Sheng X, Pooler L, Haiman CA, Sucheston-Campbell L, Hahn T, Hansen JA.

Blood. 2016 Nov 17;128(20):2450-2456. Epub 2016 Oct 6.


Late acute graft-versus-host disease: a prospective analysis of clinical outcomes and circulating angiogenic factors.

Holtan SG, Khera N, Levine JE, Chai X, Storer B, Liu HD, Inamoto Y, Chen GL, Mayer S, Arora M, Palmer J, Flowers MED, Cutler CS, Lukez A, Arai S, Lazaryan A, Newell LF, Krupski C, Jagasia MH, Pusic I, Wood W, Renteria AS, Yanik G, Hogan WJ, Hexner E, Ayuk F, Holler E, Watanaboonyongcharoen P, Efebera YA, Ferrara JLM, Panoskaltsis-Mortari A, Weisdorf D, Lee SJ, Pidala J.

Blood. 2016 Nov 10;128(19):2350-2358. doi: 10.1182/blood-2015-09-669846. Epub 2016 Sep 13.


National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Research Methodology and Study Design Working Group Report.

Shaw BE, Hahn T, Martin PJ, Mitchell SA, Petersdorf EW, Armstrong GT, Shelburne N, Storer BE, Bhatia S.

Biol Blood Marrow Transplant. 2017 Jan;23(1):10-23. doi: 10.1016/j.bbmt.2016.08.018. Epub 2016 Aug 30. Review.


Lung Function Trajectory in Bronchiolitis Obliterans Syndrome after Allogeneic Hematopoietic Cell Transplant.

Cheng GS, Storer B, Chien JW, Jagasia M, Hubbard JJ, Burns L, Ho VT, Pidala J, Palmer J, Johnston L, Mayer S, Crothers K, Pusic I, Lee SJ, Williams KM.

Ann Am Thorac Soc. 2016 Nov;13(11):1932-1939.


Marrow grafts from HLA-identical siblings for severe aplastic anemia: does limiting the number of transplanted marrow cells reduce the risk of chronic GvHD?

Gallo S, Woolfrey AE, Burroughs LM, Storer BE, Flowers ME, Hari P, Pulsipher MA, Heimfeld S, Kiem HP, Sandmaier BM, Storb R.

Bone Marrow Transplant. 2016 Dec;51(12):1573-1578. doi: 10.1038/bmt.2016.198. Epub 2016 Aug 1.


Genetic risk factors for sclerotic graft-versus-host disease.

Inamoto Y, Martin PJ, Flowers ME, Lee SJ, Carpenter PA, Warren EH, Geraghty DE, Lee N, Boeckh MJ, Storer BE, Levine DM, Fan W, Zhao LP, Hansen JA.

Blood. 2016 Sep 15;128(11):1516-24. doi: 10.1182/blood-2016-05-715342. Epub 2016 Jun 16.


Comorbidities, Alcohol Use Disorder, and Age Predict Outcomes after Autologous Hematopoietic Cell Transplantation for Lymphoma.

Graf SA, Vaughn JE, Chauncey TR, Storer BE, Gopal AK, Holmberg LA, McCune JS, Bensinger WI, Maloney DG, Press OW, Storb R, Sorror ML.

Biol Blood Marrow Transplant. 2016 Sep;22(9):1582-1587. doi: 10.1016/j.bbmt.2016.06.007. Epub 2016 Jun 14.


Adjuvant Radiation Therapy and Chemotherapy in Merkel Cell Carcinoma: Survival Analyses of 6908 Cases From the National Cancer Data Base.

Bhatia S, Storer BE, Iyer JG, Moshiri A, Parvathaneni U, Byrd D, Sober AJ, Sondak VK, Gershenwald JE, Nghiem P.

J Natl Cancer Inst. 2016 May 31;108(9). pii: djw042. doi: 10.1093/jnci/djw042. Print 2016 Sep.


Response of Steroid-Refractory Acute GVHD to α1-Antitrypsin.

Marcondes AM, Hockenbery D, Lesnikova M, Dinarello CA, Woolfrey A, Gernsheimer T, Loghman-Adham M, Gelmont D, Storer B, Hansen JA, Deeg HJ.

Biol Blood Marrow Transplant. 2016 Sep;22(9):1596-1601. doi: 10.1016/j.bbmt.2016.05.011. Epub 2016 May 17.

Supplemental Content

Loading ...
Support Center